Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €50.23 EUR
Change Today +2.00 / 4.15%
Volume 3.9K
NOVA On Other Exchanges
Symbol
Exchange
OTC US
Mexico
Frankfurt
Frankfurt
As of 1:16 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€49.15
Previous Close
€48.22
Day High
€50.23
Day Low
€48.18
52 Week High
08/6/15 - €56.06
52 Week Low
10/16/14 - €32.50
Market Cap
130.6B
Average Volume 10 Days
5.3K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
€0.77
Dividend Yield
1.37%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,658 Employees
Last Reported Date: 08/6/15
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr15.2M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Executive Vice President of China, Pacific & ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk to Invest $1.2 Billion

Novo Nordisk will build a $1.2 billion manufacturing facility in Johnston County and add 691 jobs there in the coming five years.

Novo Nordisk to Invest $2 Billion in New Production Facilities in North Carolina and Denmark

Novo Nordisk A/S announced that it plans to invest an estimated $2 billion over the next five years in new production facilities in Clayton, North Carolina and Malov, Denmark to support the increasing demand for diabetes medicine. The final design and cost of the planned production facilities will be presented to the company's board in 2016, and the facilities are expected to be operational during 2020.

Novo Nordisk Announces Headline Results from Second and Final Phase 3a Trial with Liraglutide as Adjunct Therapy to Insulin for People with Type 1 Diabetes

Novo Nordisk announced headline results from the second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes. ADJUNCT ONETM is a randomised, double-blind, placebo-controlled trial investigating efficacy and safety of daily doses of 0.6 mg, 1.2 mg and 1.8 mg liraglutide compared with placebo as adjunct to insulin treatment. 1,398 people with type 1 diabetes were treated for 52 weeks. From a mean baseline HbA1c of around 8.2%, people treated with 1.2 mg and 1.8 mg liraglutide as adjunct to insulin therapy achieved the primary objective of non-inferiority in HbA1c and showed a greater improvement in HbA1c of around 0.5% compared with 0.3% for people treated with placebo. The primary objective of HbA1c non-inferiority was not confirmed for the 0.6 mg dose. Furthermore, from a mean baseline weight of around 86 kg, people treated with 1.2 mg and 1.8 mg liraglutide as adjunct to insulin therapy achieved a statistically significantly greater weight loss between 3 kg and 4 kg whereas people treated with placebo experienced a weight gain of around 1 kg. In the trial, the most common adverse events were related to the gastrointestinal system, primarily transient nausea and vomiting. The rate of severe hypoglycaemia appeared numerically, but not statistically significantly lower for all doses of liraglutide as adjunct to insulin therapy compared with placebo. A statistically significant higher rate of confirmed symptomatic hypoglycaemia was observed among people treated with liraglutide 1.2 mg and 1.8 mg compared with people treated with placebo. The proportion of people with serious adverse events was similar in all treatment groups. Based on a risk/benefit assessment of the overall dataset from the two ADJUNCT trials, Novo Nordisk does currently not intend to submit an application to expand the label of Victoza for use in type 1 diabetes. Novo Nordisk intends to conduct thorough analyses to evaluate the clinical data and define potential future clinical and regulatory initiatives.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €50.23 EUR +2.00

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $64.51 USD +1.37
Allergan plc $312.00 USD +6.02
Amgen Inc $155.72 USD +1.74
Bristol-Myers Squibb Co $60.82 USD +0.79
Eli Lilly & Co $83.74 USD +2.64
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 30.2x
Price/Sales 9.4x
Price/Book 23.9x
Price/Cash Flow 23.9x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.